Novartis’ new heart failure drug, Entresto has been fast-tracked thru the FDA, but FDA approval isn’t everything. Entresto has been quoted at $12.50/day compared to $10/three months for current ACE inhibitors. Will Novartis be able to find a price payers will be happy with? Read more here. (Source: Tracey Walker, Managed Healthcare Executive, 8/18/15)
You are here: / / Will New Heart Failure Drug Find a Price That Works for Payers?